Deal value, however, was up, boosted by high-dollar-figure agreements: The 2025 deals tracked by Pitchbook totaled roughly $2.4 trillion in deal value, compared with roughly $1.83 trillion in 2024. The data represents both corporate M&A and private equity buyout activity and considers both announced and closed transactions. In particular, middle-market deal volume was low this year with those large M&A transactions padding the stats, according to a S&P Global analysis of dealmaking as of November. "This has ...

AGF expects to issue a press release on or about December 30, 2025, which will provide the final cash distribution amounts, which may vary from the estimated amounts disclosed below. Generally, the estimated "per unit" distribution is expected to increase if the net units outstanding of the AGF Investment ETF decreases between December 19, 2025 and December 30, 2025 or may change as a result of other unforeseen reasons. Details regarding the estimated "per unit" cash distribution amounts are as follows: TOR ...

Winnipeg, Manitoba--(Newsfile Corp. - December 19, 2025) - Snow Lake Resources Ltd., d/b/a Snow Lake Energy (NASDAQ: LITM) ("Snow Lake"), a nuclear fuel cycle company, announces that Ubaryon has provided a shareholder update which conveys that Ubaryon is making significant progress on its 100% owned Uranium Enrichment Technology ("Ubaryon Enrichment Technology") as well as other value accretive technologies. Highlights Operational Update Uranium Technology Development As a part of the due diligence for the ...

MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy in partnership with Cube Group, through its newly formed subsidiary, M ...

Avicanna's evidence-based pathway for cannabinoid-based medicine aligns with the executive order. About Avicanna Inc Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based f ...

Avicanna's evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna's 2025 advances across R&D, clinical development, and medical affairs. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. Cautionary Note Regarding Forward-Looking Information and Statements TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceut ...

TOKYO and TAIPEI, Dec. 19, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the "Company"), a Tokyo-based next-generation digital media and data group in Asia, today issued a letter to shareholders from Joey Chung, Co-Founder and CEO, and Motoko Imada, Co-Founder and President of TNL Mediagene, discussing key recent positive and notable developments, milestones and achievements of the Company year-to- date in 2025 and plans for the year ahead. Dear Shareholders, As we conclude 2025, we want to give an upd ...

Nasdaq Contact: Nasdaq MarketWatch nasdaqmarketwatch@nasdaq.com NDAQO Trading will remain halted until Magnitude International Ltd has fully satisfied Nasdaq's request for additional information. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotes on the Nasdaq Web site. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ...

Group 1 - FinTech industry is currently facing challenges due to credit cycles and high capital requirements [1] - Pagaya Technologies (PGY) has developed a distinctive strategy that allows it to overcome these challenges [1] Group 2 - The article emphasizes the importance of identifying profitable and undervalued investment opportunities in the U.S. market [1]

Core Insights - OpenAI is seeking to raise $100 billion in funding, potentially increasing its valuation to $830 billion and paving the way for an IPO [1][2] - The company currently holds approximately 17% of the global chatbot market, primarily through its ChatGPT series [1] Funding and IPO Speculation - The funds are intended to scale OpenAI's operations and maintain competitiveness, with speculation surrounding CEO Sam Altman's potential plans for an IPO [2] - The funding round is expected to close by March 2026, but there is uncertainty regarding investor participation at the desired scale [2] Valuation and Market Predictions - Predictions suggest that the $100 billion funding could lead to a public-market valuation between $900 billion and $1.05 trillion, marking one of the largest IPOs in history [4] - The anticipated public float is estimated to be between 12% and 15%, with a 15% float being most likely to ensure liquidity and meet investor demand [5] Share Price Estimates - Based on a hypothetical 500 million shares outstanding, the estimated stock prices are $2,000 per share at a $1 trillion valuation, $1,800 at $900 billion, and $2,100 at $1.05 trillion [8] - The analysis indicates that substantial pre-IPO funding could dilute existing shareholders, affecting ownership percentages and market perception [7][9]